FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   | Address of Rep | porting Person* | Requiring S<br>(Month/Day                                      | 2. Date of Event Requiring Statement (Month/Day/Year) 03/01/2023  3. Issuer Name and Ticker or Trading Symbol MYRIAD GENETICS INC [ MYGN ] |   |  |              |  |  |  |  |
|---|----------------|-----------------|--|--|---|--|--------------|--|--|--|--|
| (Last) (First) (Middle) 320 WAKARA WAY  |                |                 |  |  | Relationship of Reportin<br>Issuer<br>(Check all applicable)     Director |  | Person(s) to |  | 5. If Amendment, Date of Original Filed (Month/Day/Year) |  |  |
| (Street) SALT LAKE CITY (City)  | UT (State)     | 84108<br>(Zip)  |  |  | X Officer (give title below)  Chief People                                | Other (specify below)                  |              | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |  |  |
| Table I - Non-Derivative Securities Beneficially Owned  |                |                 |  |  |   |  |              |  |  |  |  |
| 1. Title of Security (Instr. 4)   |                |                 |  |  | 2. Amount of Securities<br>Beneficially Owned (Instr.<br>I)               |  |              | 4. Nature of Indirect Beneficial<br>Ownership (Instr. 5)   |  |  |  |
| Table II - Derivative Securities Beneficially Owned<br>(e.g., puts, calls, warrants, options, convertible securities) |                |                 |  |  |   |  |              |  |  |  |  |
|   |                |                 | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |  | 3. Title and Amount of S<br>Underlying Derivative S<br>(Instr. 4)         |  |              |  | 5.<br>Ownership<br>Form:                                 | 6. Nature of<br>Indirect Beneficial<br>Ownership (Instr. |  |
|   |                |                 | Date<br>Exercisable  | Expiration<br>Date   | Title   | Amount<br>or<br>Number<br>of<br>Shares |              | ve   | Direct (D)<br>or Indirect<br>(I) (Instr. 5)              | 5)   |  |

**Explanation of Responses:** 

## Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

By: Justin Hunter For: Shereen Solaiman 03/02/2023

\*\* Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of R. Bryan Riggsbee, Pamela Wong, Natalie Munk, and Justin Hunter of Myriad Genetics, Inc. (the "Company"), signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3,4 or 5, complete and execute any amendments thereto, and timely file such form with the United States Securities and Exchange Commission (the SEC) and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to each of the undersigned's attorneys-in-fact appointed by this Power of Attorney and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the

undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 17th day of February, 2023.

/S/ Shereen Solaiman

Shereen Solaiman